Zacks Investment Research downgraded shares of Entellus Medical, Inc. (NASDAQ:ENTL) from a hold rating to a sell rating in a report issued on Tuesday morning.
According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “
ENTL has been the subject of several other research reports. ValuEngine lowered Entellus Medical from a sell rating to a strong sell rating in a report on Tuesday, May 23rd. BidaskClub lowered Entellus Medical from a strong-buy rating to a buy rating in a report on Saturday, July 8th. Canaccord Genuity lowered Entellus Medical from a buy rating to a hold rating and cut their price objective for the company from $22.00 to $18.00 in a report on Thursday, May 4th. Finally, William Blair restated an outperform rating on shares of Entellus Medical in a report on Wednesday, May 10th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Entellus Medical currently has a consensus rating of Hold and an average target price of $21.83.
Entellus Medical (ENTL) traded down 1.13% on Tuesday, hitting $17.47. The stock had a trading volume of 199,556 shares. Entellus Medical has a one year low of $11.47 and a one year high of $22.63. The stock has a 50-day moving average of $13.90 and a 200-day moving average of $15.35. The company’s market cap is $382.87 million.
Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings data on Wednesday, May 3rd. The medical technology company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.04. The business had revenue of $19.11 million during the quarter, compared to analyst estimates of $19.61 million. Entellus Medical had a negative return on equity of 60.56% and a negative net margin of 39.02%. The company’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. Equities analysts expect that Entellus Medical will post ($1.37) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Downgrades Entellus Medical, Inc. (NASDAQ:ENTL) to Sell” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2723760/zacks-investment-research-downgrades-entellus-medical-inc-nasdaqentl-to-sell.html.
In related news, CFO Brent Moen bought 6,100 shares of Entellus Medical stock in a transaction dated Monday, May 8th. The stock was acquired at an average cost of $12.21 per share, with a total value of $74,481.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Robert S. White bought 10,000 shares of Entellus Medical stock in a transaction dated Monday, May 8th. The shares were bought at an average cost of $12.24 per share, with a total value of $122,400.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 17,700 shares of company stock valued at $216,625. 9.10% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the stock. Frontier Capital Management Co. LLC acquired a new stake in shares of Entellus Medical during the first quarter valued at about $6,464,000. William Blair Investment Management LLC increased its stake in shares of Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock valued at $5,387,000 after buying an additional 355,388 shares in the last quarter. Kingdon Capital Management L.L.C. increased its stake in shares of Entellus Medical by 79.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock valued at $6,215,000 after buying an additional 199,615 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its stake in shares of Entellus Medical by 868.1% in the first quarter. Grandeur Peak Global Advisors LLC now owns 212,491 shares of the medical technology company’s stock valued at $2,932,000 after buying an additional 190,541 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Entellus Medical by 77.8% in the first quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after buying an additional 185,833 shares in the last quarter. 75.79% of the stock is owned by institutional investors and hedge funds.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.